Back to results
US 12,178,830 B2Granted
Compositions and methods for adoptive cell therapy for cancer
AssigneeMemorial Sloan Kettering Cancer Center
InventorsDavid A. Scheinberg, Thomas J. Gardner, Derek S. Tan, Jonghan Lee
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.
Claims13
An engineered immune cell comprising:
- (a) a nucleic acid encoding a prodrug converting enzyme;
- and
- (b) a receptor comprising a first transmembrane domain, wherein the receptor is expressed on the surface of the immune cell and binds to a tumor antigen expressed on solid tumors,
- wherein the prodrug converting enzyme is:
- (i secreted from the engineered immune cell, or
- (ii) expressed on the surface of the engineered immune cell and is
- (A) attached to the surface of the cell by a GPI anchor;
- or
- (B) fused to a second transmembrane domain;
- and
- wherein the first transmembrane domain of the receptor is separate from the second transmembrane domain of the prodrug converting enzyme, and wherein the engineered immune cell treats solid tumors that are resistant to CAR T cell therapy.
8 more elements
Dependencies are inferred from the claim text.